DOP2021000206A - Inhibidores de la proteína tirosina fosfatasa - Google Patents
Inhibidores de la proteína tirosina fosfatasaInfo
- Publication number
- DOP2021000206A DOP2021000206A DO2021000206A DO2021000206A DOP2021000206A DO P2021000206 A DOP2021000206 A DO P2021000206A DO 2021000206 A DO2021000206 A DO 2021000206A DO 2021000206 A DO2021000206 A DO 2021000206A DO P2021000206 A DOP2021000206 A DO P2021000206A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- protein tyrosine
- tyrosine phosphatase
- phosphatase inhibitors
- tautomer
- stereoisomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos de la Fórmula I o un estereoisómero, tautómero, profármaco o sal aceptable desde el punto de vista farmacéutico de este, que son útiles para la fabricación de medicamentos útiles en el tratamiento de enfermedades hiperproliferativas. Se divulgan métodos para usar los compuestos de la Fórmula I o un estereoisómero, tautómero, profármaco o sal aceptable desde el punto de vista farmacéutico de estos, para el diagnóstico in vitro, in situ e in vivo, la prevención o el tratamiento de dichos trastornos en células de mamífero, o las afecciones patológicas relacionadas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828356P | 2019-04-02 | 2019-04-02 | |
| US202062992558P | 2020-03-20 | 2020-03-20 | |
| PCT/IB2020/053019 WO2020201991A1 (en) | 2019-04-02 | 2020-03-30 | Protein tyrosine phosphatase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000206A true DOP2021000206A (es) | 2021-11-21 |
Family
ID=70277430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000206A DOP2021000206A (es) | 2019-04-02 | 2021-09-30 | Inhibidores de la proteína tirosina fosfatasa |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11634417B2 (es) |
| EP (1) | EP3947367A1 (es) |
| JP (2) | JP7284830B2 (es) |
| KR (1) | KR102698608B1 (es) |
| CN (1) | CN113874363A (es) |
| AU (1) | AU2020251841A1 (es) |
| BR (1) | BR112021018664A2 (es) |
| CA (1) | CA3135555C (es) |
| CL (2) | CL2021002542A1 (es) |
| CO (1) | CO2021013030A2 (es) |
| CR (1) | CR20210501A (es) |
| CU (1) | CU20210080A7 (es) |
| DO (1) | DOP2021000206A (es) |
| EC (1) | ECSP21072994A (es) |
| GE (1) | GEP20237561B (es) |
| IL (1) | IL286462A (es) |
| MA (1) | MA55511A (es) |
| MX (1) | MX2021012122A (es) |
| PE (1) | PE20220141A1 (es) |
| SG (1) | SG11202110502PA (es) |
| TW (1) | TWI766261B (es) |
| UY (1) | UY38628A (es) |
| WO (1) | WO2020201991A1 (es) |
| ZA (1) | ZA202108443B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| JP7284830B2 (ja) * | 2019-04-02 | 2023-05-31 | アレイ バイオファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ阻害剤 |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ｒａｓ阻害剤としてのインドール誘導体 |
| WO2022206684A1 (zh) * | 2021-03-31 | 2022-10-06 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| EP4313307A1 (en) | 2021-04-01 | 2024-02-07 | Array Biopharma Inc. | Crystalline form of a shp2 inhibitor |
| JP2024517847A (ja) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技（上海）有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
| CN115960109B (zh) * | 2021-05-31 | 2024-06-25 | 药雅科技(上海)有限公司 | 稠环类shp2磷酸酶抑制剂的制备及其应用 |
| KR102682323B1 (ko) | 2021-07-09 | 2024-07-09 | 주식회사 카나프테라퓨틱스 | Shp2 억제제 및 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20240089564A (ko) * | 2021-10-14 | 2024-06-20 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Shp2 억제제, 이를 포함하는 약학적 조성물 및 이의 용도 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| AU2023238523A1 (en) | 2022-03-23 | 2024-08-22 | Array Biopharma Inc. | Crystalline salt form of a shp2 inhibitor |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN115177622B (zh) * | 2022-07-19 | 2024-09-17 | 中南大学湘雅二医院 | 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用 |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US7834178B2 (en) | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
| US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| UA116875C2 (uk) | 2011-10-14 | 2018-05-25 | Еррей Біофарма Інк. | Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять |
| MX369989B (es) | 2012-08-27 | 2019-11-27 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas. |
| DK3053923T3 (en) | 2013-09-30 | 2018-07-23 | Korea Res Inst Chemical Tech | TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS |
| EP3094629B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| US10975080B2 (en) | 2015-06-19 | 2021-04-13 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| US10308660B2 (en) | 2015-06-19 | 2019-06-04 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| JP6718889B2 (ja) * | 2015-06-19 | 2020-07-08 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| KR20230109185A (ko) | 2016-06-07 | 2023-07-19 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| TWI806832B (zh) * | 2016-07-12 | 2023-07-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TWI848901B (zh) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| US10988466B2 (en) * | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| CA3074304A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| RU2020115095A (ru) | 2017-10-12 | 2021-11-12 | Революшн Медсинз, Инк. | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| SG11202009245TA (en) | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201940167A (zh) | 2018-03-21 | 2019-10-16 | 美商新標利亞治療藥物公司 | Shp2抑制劑及其用途 |
| EP3768680A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| IL280701B2 (en) | 2018-08-10 | 2024-03-01 | Navire Pharma Inc | History of 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3,2-dichlorophenyl)-2-methylpyrimidin-4(H3)-one and compounds associated as PTPN11 (SHP2) inhibitors for cancer treatment |
| WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| JP7449282B2 (ja) | 2018-10-17 | 2024-03-13 | アレイ バイオファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ阻害薬 |
| JP7284830B2 (ja) * | 2019-04-02 | 2023-05-31 | アレイ バイオファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ阻害剤 |
-
2020
- 2020-03-30 JP JP2021558566A patent/JP7284830B2/ja active Active
- 2020-03-30 MX MX2021012122A patent/MX2021012122A/es unknown
- 2020-03-30 KR KR1020217035641A patent/KR102698608B1/ko active IP Right Grant
- 2020-03-30 CU CU2021000080A patent/CU20210080A7/es unknown
- 2020-03-30 CA CA3135555A patent/CA3135555C/en active Active
- 2020-03-30 MA MA055511A patent/MA55511A/fr unknown
- 2020-03-30 GE GEAP202015746A patent/GEP20237561B/en unknown
- 2020-03-30 PE PE2021001646A patent/PE20220141A1/es unknown
- 2020-03-30 EP EP20718387.2A patent/EP3947367A1/en active Pending
- 2020-03-30 SG SG11202110502PA patent/SG11202110502PA/en unknown
- 2020-03-30 CN CN202080036271.6A patent/CN113874363A/zh active Pending
- 2020-03-30 WO PCT/IB2020/053019 patent/WO2020201991A1/en active Application Filing
- 2020-03-30 CR CR20210501A patent/CR20210501A/es unknown
- 2020-03-30 AU AU2020251841A patent/AU2020251841A1/en active Pending
- 2020-03-30 BR BR112021018664A patent/BR112021018664A2/pt unknown
- 2020-03-31 US US16/835,702 patent/US11634417B2/en active Active
- 2020-04-01 UY UY0001038628A patent/UY38628A/es unknown
- 2020-04-01 TW TW109111284A patent/TWI766261B/zh active
-
2021
- 2021-09-19 IL IL286462A patent/IL286462A/en unknown
- 2021-09-29 CO CONC2021/0013030A patent/CO2021013030A2/es unknown
- 2021-09-30 DO DO2021000206A patent/DOP2021000206A/es unknown
- 2021-09-30 EC ECSENADI202172994A patent/ECSP21072994A/es unknown
- 2021-09-30 CL CL2021002542A patent/CL2021002542A1/es unknown
- 2021-10-29 ZA ZA2021/08443A patent/ZA202108443B/en unknown
-
2022
- 2022-04-13 US US17/720,070 patent/US11884664B2/en active Active
-
2023
- 2023-03-27 JP JP2023049681A patent/JP2023078421A/ja active Pending
- 2023-11-17 US US18/512,473 patent/US20240124453A1/en active Pending
-
2024
- 2024-01-19 CL CL2024000183A patent/CL2024000183A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000206A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| DOP2021000070A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| CY1120172T1 (el) | Αναστολεις κινασων σερινης/θρεονινης | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| MX2021015935A (es) | Formas de sal de acido bempedoico y metodos para utilizar el mismo. | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| EA201101497A1 (ru) | Имидазопираны для применения в качестве ингибиторов киназ | |
| EA200702200A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| PA8779701A1 (es) | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido | |
| EA202090052A1 (ru) | Содержащие имидазол ингибиторы alk2 киназы | |
| UY38096A (es) | Inhibidores de arginasa y sus métodos de uso | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| CL2021000515A1 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| BR112021014881A2 (pt) | Composto de poliol anti-hipertensivo e derivados do mesmo | |
| EA202190801A1 (ru) | Ингибиторы протеинтирозинфосфатазы | |
| UY38946A (es) | Pirrolopiridinas como inhibidores de cinasa | |
| ES2982398T3 (es) | Compuestos novedosos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades renales | |
| EA201992577A1 (ru) | 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |